DAIICHI-SANKYO
10.7.2024 12:07:31 CEST | Business Wire | Press release
Daiichi Sankyo (TSE: 4568) today announced that it has opened a new affiliate for its oncology business in Athens, Greece. The establishment highlights the company’s strong commitment to addressing treatment needs of people living with cancer in the European region. Thomais Konstantopoulou has been appointed Country Manager, Daiichi Sankyo Greece Single Member S.A.
“We are very happy to open yet another new affiliate in Europe to bring our innovative medicines to patients who can benefit from them. To have representation in a country is the best way of doing this,” said Thomais Konstantopoulou, Country Manager, Daiichi Sankyo Greece. “Our decision to establish a presence in Greece stems from our deep-rooted commitment to serving as many patients with cancer as possible with our innovative portfolio, aiming to improve outcomes and quality of life. It also is linked to a continuous effort of multiple stakeholders that elevates oncology in the country’s healthcare agenda and promotes active dialogue. Daiichi Sankyo is investing in Greece, which aligns with the country’s ambition to create conditions that foster innovation, talent retention, technology advancement and economic growth. We are focused on advancing meaningful innovation and creating jobs in a sustainable manner.”
Daiichi Sankyo has affiliates in 14 European countries, alongside representations in Norway, Finland, Sweden and Luxembourg. Europe has always been a focus for the company’s medicines, as well as a key region for continuous investment. With 20 research and development sites across 12 countries, Daiichi Sankyo utilizes a global network to drive innovation. Currently, the company is focused on developing antibody drug conjugates (ADCs), which are targeted cancer medicines that combine target-specificity and anti-tumor activity in a single molecule.
“From pursuing new medicines and new methods of drug discovery and delivery to achieving excellence throughout our organization by continuously examining new ideas, innovation is paramount for all we do,” said Dr. Dimitrios Krikelis, Head of Medical Affairs, Daiichi Sankyo Greece. “Even before the establishment of the Greek affiliate, Daiichi Sankyo has been partnering with the local oncology community through our clinical development program. We are fortunate to have physicians with a wealth of clinical expertise and a vibrant research community in Greece.”
Daiichi Sankyo aims to be an active contributor to the Greek healthcare ecosystem by partnering with the scientific community, governmental organizations and patient advocacy groups in order to provide value to patients, healthcare professionals and health authorities.
About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit www.daiichi-sankyo.eu.
HQ/ONP/07/24/0007
| _______________________________ |
1 https://www.jto.org/article/S1556-0864(20)31099-6/fulltext |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709254444/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aircall Acquires Vogent to Advance Its AI Voice Agent Built Natively into Business Phones6.5.2026 12:03:00 CEST | Press release
Aircall, the AI-powered customer communications platform trusted by more than 22,000 businesses worldwide, today announced the acquisition of Vogent, an AI voice agent company. The acquisition adds a new layer of specialized voice AI technology to Aircall’s platform – strengthening the technology behind Aircall’s AI Voice Agent and moving it from already great to best-in-class. While AI agents' chat or email based communication channels have exploded in popularity, voice is its own discipline – with unique demands around timing, interruption handling, call flows, and production reliability. Voice channel also comes with the highest expectations from customers, further putting scrutiny around the readiness of the technology. For many businesses deploying AI voice agents, the experience has not lived up to the hype. With Vogent, Aircall enhances its AI Voice Agents with a deeper set of specialized AI technologies, including advanced speech models, more reliable turn-taking, and higher pr
AB InBev Wins Cannes Lions Creative Marketer of the Year for an Unprecedented Third Time6.5.2026 12:03:00 CEST | Press release
The world’s leading brewer’s approach to creativity as a competitive advantage results in strong performance and increased revenues The Cannes Lions International Festival of Creativity has announced AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD) as the 2026 Creative Marketer of the Year. The honorary accolade is presented to a marketer that has amassed a body of iconic, Lion-winning work over a sustained period of time. AB InBev’s continued commitment to using creativity as a growth lever across its portfolio resulted in it winning an impressive 37 Lions at last year’s Festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506536538/en/ AB InBev is the first company in Cannes Lions’ history to be honoured with the award for a third time. Since 2021 the global brewer has embarked on a journey of inorganic to organic growth, betting on creativity as a key competitive advantage that has contributed to strong perfor
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates6.5.2026 12:00:00 CEST | Press release
Total global revenues of $1.5 billion for the first quarter, an increase of 35% from the prior year Foundational BRUKINSA (zanubrutinib) global revenues of $1.1 billion for the first quarter, an increase of 38% from the prior year Diluted GAAP Earnings per American Depository Share (ADS) of $1.96 for the first quarter; non-GAAP diluted Earnings per ADS of $3.24 for the first quarter BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the first quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “These strong first-quarter results reinforce BeOne’s continued growth as a global oncology leader, driven by disciplined commercial execution, and underpinned by our established hematology leadership, and an impressive, rapidly emerging solid tumor pipeline. The sustained competitive advantages of our global superhighway for clinical development and manufacturing are now cle
Type One Energy, Tokamak Energy, and AECOM Form the UK Infinity Fusion Consortium to Accelerate Development of a Commercial Fusion Power Plant in the United Kingdom6.5.2026 10:00:00 CEST | Press release
Type One Energy, Tokamak Energy, and AECOM today announced the UK Infinity Fusion Consortium to pursue development of the first private-sector-led fusion power plant project in the United Kingdom. Together, the companies intend to develop a fusion project that is commercially credible, deployable using existing enabling technologies, and capable of attracting private capital — consistent with the long-term goals of the government’s recently announced UK Fusion Strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506129586/en/ (From left to right) Warrick Matthews, CEO of Tokamak Energy; Chris Mowry, CEO of Type One Energy; and Troy Rudd, Chairman and CEO of AECOM sign the UK Infinity Fusion Consortium during His Majesty King Charles III’s visit to New York City. This announcement comes at a time of increasing U.S.-U.K. bilateral cooperation on fusion. His Majesty King Charles III said during his address to the United
59% of Organizations Made a "Bad AI Hire" in the Past Year, New TestGorilla Research Reveals6.5.2026 10:00:00 CEST | Press release
Study of nearly 2,000 senior hiring leaders finds 53% now prioritize AI fluency over domain expertise, but a critical gap between definitions and measurement is producing confident wrong hires on both sides of the Atlantic TestGorilla, the leading skills-based hiring platform, today released The State of Hiring for AI Fluency, revealing a fundamental shift in talent evaluation: AI fluency has overtaken domain expertise as the top hiring priority. 53% of hiring managers now prefer candidates with strong AI fluency over deep subject matter experts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506155219/en/ TestGorilla's The State of Hiring for AI Fluency Report Reveals a Transatlantic Divide between US and UK: Study of nearly 2,000 senior hiring leaders finds 53% now prioritize AI fluency over domain expertise, but a critical gap between definitions and measurement is producing confident wrong hires on both sides of the A
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom